HIỆU QUẢ CỦA PHÁC ĐỒ BỐN THUỐC CÓ BISMUTH  TRONG ĐIỀU TRỊ TIỆT TRỪ HELICOBACTER PYLORI

Trung Võ Nguyên; Hân Trần Thị Ngọc; Huyền Trần Thị Thu; Hùng Nguyễn Đại; Chinh Nguyễn Văn; Tùng Lê Việt; Vinh Nguyễn Quốc

doi:10.59354/ydth175.2024.290

Keywords:

Helicobacter pylori, Bismuth-containing quadruple regimen, Helicobacter pylori eradication

Abstract

Purpose: To determine the success rate of Helicobacter pylori (H. pylori) eradication using a Bismuth-containing quadruple regimen, identify factors related to the effectiveness of this regimen, and determine the rate of side effects associated with the Bismuth-containing quadruple regimen.

Methods: This prospective cohort study involved cases of H. pylori infection diagnosed by gastroscopy, treated with the Bismuth-containing quadruple regimen, and re-evaluated using a breath test at Branch 2 - the University Medical Center Ho Chi Minh City from March 2023 to July 2024.

Results: The success rate of H. pylori eradication in the study was 73.8% according to ITT (Intention to Treat) analysis and 91.4% according to PP (Per Protocol) analysis. No factors related to the treatment’s effectiveness were found. 53% of cases experienced side effects during treatment. The most common side effects were nausea (50%), fatigue (48.8%), bitter taste (40%), bloating (26.3%), and early satiety (36.3%). Most of these symptoms were mild (>50%).

Conclusion: The Bismuth-containing quadruple regimen indicated in our study for H. pylori eradication is highly effective. The regimen is commonly associated with side effects, the most frequent being nausea, fatigue, and a bitter taste.

References

Wroblewski LE, Peek RM, Wilson KT (2010). Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev, 23(4), 713-739.

Savoldi A, Carrara E, Graham DY, et al (2018). Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology, 155(5), 1372-1382.

Rahman R, Asombang AW, Ibdah JA (2014). Characteristics of gastric cancer in Asia. World J Gastroenterol, 20(16), 4483-4490.

Khien VV, Thang DM, Hai TM, et al (2019). Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam. Gut Liver, 13(5), 483-497.

Quach DT, Vilaichone RK, Vu KV, et al (2018). Helicobacter pylori Infection and Related Gastrointestinal Diseases in Southeast Asian Countries: An Expert Opinion Survey. Asian Pac J Cancer Prev, 19(12), 3565-3569.

Malfertheiner P, Megraud F, O’Morain CA, et al (2017). Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut, 66(1), 6-30.

Quach DT, Mai BH, Tran MK, et al (2022). Vietnam Association of Gastroenterology (VNAGE) consensus on the management of Helicobacter pylori infection. Front Med (Lausanne), 9, 1065045.

Shao QQ, Yu XC, Yu M, et al (2022). Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomizedcontrolled trial. Helicobacter, 27(2), e12876.

Đặng Ngọc Quý Huệ (2018). Nghiên cứu tỉ lệ kháng Clarithromycin, Levofloxacin của Helicobacter pylori bằng Epsilometer và hiệu quả của phác EBMT ở bệnh nhân viêm dạ dày mạn. Luận án tiến sĩ y học.

Sapmaz F, Kalkan IH, Atasoy P, et al (2017). A Non-Inferiority Study: Modified Dual Therapy Consisting Higher Doses of Rabeprazole Is as Successful as Standard Quadruple Therapy in Eradication of Helicobacter pylori. Am J Ther, 24(4), e393-e398.

Nam CB, Khien VV, Hoan QP, et al (2016). Efficacy of Helicobacter Pylori eradication therapy with PCA, PTMB, PLA. Viet. Nam. Gastroenterol. Assoc, 45, 2851–2854.

Nguyen LT, Nguyen VB, Tran TV, et al (2022). Efficacy of Helicobacter pylori Eradication Based on Rabeprazole–Bismuth–Tetracycline–Tinidazole Regimen in Vietnamese Patients with Duodenal Ulcers. Gastroenterol. Insights, 13, 365–376.